. Author manuscript; available in PMC: 2020 Jul 27.

Published in final edited form as: Biol Blood Marrow Transplant. 2019 Mar 12;25(7):1355–1362. doi: 10.1016/j.bbmt.2019.03.008

Table 3.

Immune Reconstitution at 6 months, 12 months, and Last Follow Up

	6 month Evaluation		12 month Evaluation			Time to off IVIG(years)	At Last F/U Evaluation
UPN	CD4 (x10^6/L)	CD4/CD45RA (x10^6/L)	CD4 (x10^6/L)	CD4/CD45RA (x10^6/L)	TRECs	Time to off IVIG(years)	Last F/U (years)	T cellChimerism	B cell Chimerism	Myeloid Chimerism	CD4 (x10^6/L)	CD4/CD45RA (x10^6/L)
33	570	125	1567	925	99	1.0	7.5	100%	100%	100%	1092	699
1713	191	42	385	128	ND (14 @ 20 mo)	NR	4.2	99%	94%	42%	324	117
1740	576	374	1161	824	64	0.8	5.9	95%	8%	5%	1378	661
1799	1220	537	1104	464	ND	0.6	5.0	98%	2%	5%	1122	292
1835	1307	384	1438	820	ND (476 @ 24 mo)	0.8	5.0	93%	99%	83%	1739	742
1837	304	119	600	312	17	1.4	4.9	95%	76%	3%	408	73
1875	17	0	NR^*	NR^*	NR^*	NR^*	0.9^*	80%	50%	1%^*	18^*	0^*
1947	894	378	923	443	ND	NR^{^}	3.5	98%	82%	14%	818	622
2046	683	423	897	601	117	1.7	2.0	97%	92%	8%	1345	474
2078	87	27	297	95	5	NR^{^}	2.0	92%	33%	78%	204	82

Bolded indicates a value considered to be ‘normal’ per institutional definition (see text).

TRECs, T cell receptor excision circles; IVIG, Intravenous Immunoglobulin; NR, Not Reached; ND, Not Done.

^{^}

Received rituximab for treatment of autoimmunity.

Underwent repeat conditioned HCT from a new donor and is now 100% donor in all cell lines with normal T and B cell numbers & function at 2.9 years from most recent HCT.